Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Meng-yuan Dai"'
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-4 (2024)
Abstract Since the United States Food and Drug Administration (FDA) approved the first chimeric antigen receptor T-cell (CAR-T) therapy in 2017, it has marked a major breakthrough in cancer treatment, leading to a surge in global research and applica
Externí odkaz:
https://doaj.org/article/80a08a3279c04afdb1f5a55a57018556
Autor:
Yu-Ying Shi, Gang Fan, Ruirong Tan, Shan Li, Hua-Bing Sun, Rui Li, Mengni Yang, Shanshan Gao, Miao Liu, Meng-Yuan Dai
Publikováno v:
Cell Death and Disease, Vol 15, Iss 9, Pp 1-13 (2024)
Abstract The current selection of ligands for both proteins of interest (POI) and E3 ubiquitin ligase significantly restricts the scope of targeted protein degradation (TPD) technologies. This study introduces cell-penetrating peptide-induced chimera
Externí odkaz:
https://doaj.org/article/aac14e898bd84fae9a32372bac3d450d
Autor:
Yu-Ying Shi, Gang Fan, Ruirong Tan, Shan Li, Hua-Bing Sun, Rui Li, Mengni Yang, Shanshan Gao, Miao Liu, Meng-Yuan Dai
Publikováno v:
Cell Death and Disease, Vol 15, Iss 11, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/27446c7e18f3445ca223a1e0beffca74
Publikováno v:
Cell Death and Disease, Vol 13, Iss 11, Pp 1-4 (2022)
Externí odkaz:
https://doaj.org/article/6dac064c155a425e9b912046303a8319
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionOur previous research has found that degradation of palmitoyltransferase in tumor cells using a linear peptide PROTAC leads to a significant decrease in PD-L1 expression in tumors. However, this degradation is not a sustained and efficien
Externí odkaz:
https://doaj.org/article/b0e3dff281a74a40ae2f080b55e7f559
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionImmune checkpoint inhibitors (ICIs) are monoclonal antibodies that target immune checkpoints that suppress immune cell activity. Low efficiency and high resistance are currently the main barriers to their clinical application. As a repres
Externí odkaz:
https://doaj.org/article/e6455c1ab77442e1b22d6f0afdf33318
Autor:
Shuang Ji, Meng-Yuan Dai, Yun Huang, Xiang-Chun Ren, Meng-Long Jiang, Jin-Ping Qiao, Wen-Ying Zhang, Yuan-Hong Xu, Ji-Long Shen, Ren-Quan Zhang, Guang-He Fei
Publikováno v:
Journal of Inflammation, Vol 19, Iss 1, Pp 1-16 (2022)
Abstract Background Influenza A virus (IAV) triggers acute exacerbation of chronic obstructive pulmonary disease (AECOPD), but the molecular mechanisms remain unclear. In this study, we investigated the role of IAV induced NLRP3 inflammasome activati
Externí odkaz:
https://doaj.org/article/e01466de69d24ef8a6dd3d2ef099278a
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Immune checkpoint inhibitors have made significant progress in the treatment of various cancers. However, due to the low ICI responsive rate for the gynecologic cancer, ICI two-drug combination therapy tends to be a predominant way for clinical treat
Externí odkaz:
https://doaj.org/article/b0fb696dfccf4c1cb0f8b39114485a55
Autor:
Xiao-Wen Zhang, Ru-Yu Xia, Jia-Qi Gao, Jin-Jun Liu, De-Hao Xu, Xun Li, Xiao-Yang Hu, Merlin Willcox, Michael Moore, Meng-Yuan Dai, Jeanne Trill, Yu-Tong Fei, Jian-Ping Liu
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Shufeng Jiedu (SFJD) capsules can be used as adjunctive treatment for patients with community-acquired pneumonia, but the effectiveness and safety of SFJD are not clear. This review aims to evaluate the effectiveness and safety of SFJD ba
Externí odkaz:
https://doaj.org/article/69c73dabaf6a4a2ab631b4f703775fde
Autor:
Ru-yu Xia, Xiao-yang Hu, Yu-tong Fei, Merlin Willcox, Ling-zi Wen, Ming-kun Yu, Li-shan Zhang, Meng-yuan Dai, Guang-he Fei, Mike Thomas, Nick Francis, Tom Wilkinson, Michael Moore, Jian-ping Liu
Publikováno v:
BMC Complementary Medicine and Therapies, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Chinese herbal medicine is widely used in combination with usual care for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in China. Chinese patent medicine Shufeng Jiedu (SFJD) capsules is widely used for res
Externí odkaz:
https://doaj.org/article/1e121429ce4d4ecaa1cc7aac0f349b3d